Viking Therapeutics Announces 2026 Annual Meeting Results and Election of Directors

Viking Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 19, 2026. Stockholders voted on three key proposals. First, J. Matthew Singleton and S. Kathryn Rouan, Ph.D., were elected as Class II directors to serve until the 2029 annual meeting. Second, the selection of CBIZ CPAs P.C. as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Finally, stockholders approved, on an advisory basis, the compensation of the company's named executive officers as disclosed in the proxy statement. Approximately 69.1% of the outstanding shares were represented at the meeting, constituting a quorum. The filing also noted a change in the company's principal executive office suite number in San Diego, California.